Read the latest ideas, insights and observations on the Australian Medicinal Cannabis Industry from the team at FreshLeaf Analytics.
Australia’s Most Comprehensive Medicinal Cannabis Report: Q3 2020 Thursday 17 September 2020 FreshLeaf Analytics is excited to release Australia’s most comprehensive medicinal cannabis Patient, Product
Green Fund: Australian Government Legalizes Over-The-Counter CBD
Cannabiz: Major doubts remain as industry reacts to CBD down scheduling
Stockhead Cannabis stocks were one of the rare groups in the green on a dismal day for the ASX on Wednesday following an interim ruling by the
FreshLeaf Analytics welcomes TGA interim decision on CBD down-scheduling September 9th 2020 Therapeutic Goods Administration (TGA) sticks to their guns on initial proposal for over-the-Counter
TGA Defers Decision to Pay for Epidyolex The Pharmaceutical Benefits Advisory Committee (PBAC), the body that decides whether Australians can have certain medicines subsidised by
July SASB numbers spike as Australia shoots for a more open minded future By Nisha Karyn linkedin.com/in/nishasreenivasan The Therapeutic Goods Administration (TGA) reported 5564 approvals
TGA warns medical cannabis industry about advertising regulation breaches The Therapeutic Goods Administration (TGA), Australia’s health products regulator, has issued a stern warning to the
The Export Control Legislation Amendment (Certification of Narcotic Exports) Bill 2020, which passed the Senate on June 17, will allow the Commonwealth Department of Agriculture,
A CBD product might soon be available and subsidised on the Pharmaceutical Benefits Scheme Families of children with severe drug-resistant epilepsy might soon be
NZ recreational cannabis bill released – prioritises social good over profits New Zealanders will go to the polls on September 19 to vote for their
Australian government proposes CBD be made available for retail sale Today the Therapeutic Goods Administration released the Department of Health-initiated proposal to make low-dose CBD
© 2021 All rights reserved, FreshLeaf Analytics
The H2 2021 report is FreshLeaf Analytics’ seventh market
report on patients, products and pricing in the Australian
medicinal cannabis market.
